#USA #San Francisco #Securities Class Action #Hagens Berman #PROCEPT BioRobotics

PROCEPT BioRobotics Corporation Under Legal Scrutiny

In a significant development for investors, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is facing a class action lawsuit regarding alleged securities fraud. The deadline to become a lead plaintiff in this case is September 22, 2026. The legal action has been initiated by Hagens Berman Sobol Shapiro LLP, a prominent law firm known for defending investor rights.

Background of the Case

The lawsuit arises from ongoing concerns about the company’s performance in sales of its single-use handpiece, integral to its Aquablation therapy used for treating patients with enlarged prostates. Investors who acquired PROCEPT common stock between February 28, 2024, and February 25, 2026, may be eligible to file a claim.

During this period, allegations of misleading sales practices emerged, particularly around the company's handpiece sales, which the lawsuit claims were characterized by inflated figures and questionable inventory management. The firm asserts that certain information was concealed from investors, leading to substantial financial losses.

Allegations Explained

The crux of the lawsuit is rooted in claims that PROCEPT employed aggressive discounting strategies to spur bulk orders. However, this approach, unknown to shareholders, resulted in customers accumulating excess inventory that undermined future sales. As a result, PROCEPT's reported figures portrayed an inflated view of its growth and financial stability.

Investors became increasingly aware of the discrepancies following a series of adverse announcements from the company regarding its financial results. For example, the Q2 2025 results revealed a significant drop in handpiece sales, trailing far behind analyst expectations. Subsequent reports only deepened investor concerns, as management acknowledged that customers had substantial excess inventory that negatively affected sales.

This trend continued to deteriorate, particularly evident in the Q4 2025 results which showcased a staggering 30% decline in sales due to the aforementioned inventory issues. The company also announced the cancellation of its previously undeclared bulk order discount program, which investigators argue led to the unsustainable increase in sales figures at the expense of long-term viability.

The Investor Response

The impact of these revelations was harsh and direct; by February 25, 2026, PROCEPT shares had plummeted by over 48% since their peak. This sharp decline highlights the fallout from alleged miscommunications regarding the company’s sales practices and overall health.

Hagens Berman's investigation leads with the belief that PROCEPT may have engaged in manipulative practices to create an illusion of financial success. As the investigation unfolds, investors who have faced losses are encouraged to reach out to the firm as potential contributors to the case. Those with information that could aid in the investigation are also invited to contact Hagens Berman’s legal team.

Whistleblower Program

In conjunction with this case, whistleblowers possessing non-public information are prompted to take action, particularly through the SEC Whistleblower program, which can provide significant incentivization for information sharing. Helping with this investigation could be a pivotal step in securing accountability for those affected by PROCEPT’s operations.

Conclusion

With the lead plaintiff deadline fast approaching, affected investors are urged to act swiftly. Keeping abreast of the situation, potential claimants can protect their rights and participate in efforts aimed at rectifying perceived wrongdoings. Hagens Berman remains committed to assisting those harmed by corporate misconduct while advocating for transparency and integrity in investor communications.

For more information, potential claimants and those interested in the ongoing investigation can contact Reed Kathrein at Hagens Berman.